GlassScriptPhysician profile
Aaron L Stefan
NPI 1053501023
$3,788.48
in general payments reported to CMS, 2019-2025
26 companies · $878 in 2025
The $878 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $144 · 2021: $316 · 2022: $587 · 2023: $692 · 2024: $935 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,505.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $778.26 | 2019-2025 | Cequa |
| Abbvie INC. | $480.40 | 2022-2025 | Durysta, Alphagan P, Vuity |
| Alcon Vision LLC | $460.21 | 2019-2025 | Rocklatan, Simbrinza, Eysuvis |
| Oyster Point Pharma, INC. | $421.96 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $403.41 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $214.13 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Allergan, INC. | $126.62 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $125.04 | 2021-2024 | Ultomiris |
| Biotissue Holdings INC. | $112.85 | 2022-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $110.34 | 2019-2021 | |
| Dompe US, INC. | $92.83 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $58.93 | 2019-2021 | |
| Amgen INC. | $53.69 | 2025 | Tepezza |
| Thea Pharma INC. | $47.19 | 2023-2025 | Iyuzeh |
| Harrow Eye, LLC | $44.33 | 2024-2025 | Vevye |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $42.35 | 2020-2021 | |
| Horizon Therapeutics Plc | $41.33 | 2021-2022 | |
| Omeros Corporation | $27.65 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $26.85 | 2021-2022 | |
| Rxsight INC | $21.96 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Rayner Intraocular Lenses Limited | $19.30 | 2022 | |
| Spark Therapeutics, INC. | $18.23 | 2022 | |
| Ani Pharmaceuticals, INC. | $16.17 | 2025 | Purified Cortrophin Gel |
| Argenx US, INC. | $15.97 | 2023 | Vyvgart |
| Astellas Pharma US INC | $14.85 | 2024 | Izervay |
| Eyevance Pharmaceuticals LLC | $13.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Stefan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.